Alnylam Pharmaceuticals

This study tested an experimental drug called zilebesiran in 36 Japanese adults with mild to moderate high blood pressure. The goal was to see if it is safe and helps lower blood pressure over 6 months. Participants received either the drug or a placebo, and researchers monitored…

This phase 3 trial tested the drug patisiran in 360 people with ATTR amyloidosis with cardiomyopathy, a condition where abnormal protein builds up in the heart, making it stiff and weak. Participants received either patisiran or a placebo intravenously. The study measured how far…

This study tested a new drug called zilebesiran in 375 adults with high blood pressure that wasn't controlled by their current medications. Participants received either zilebesiran or a placebo as an add-on to their usual pills. The goal was to see if zilebesiran could lower bloo…

This early-stage study tested a new drug called ALN-TTRSC04 in 96 healthy people to see if it is safe and how the body processes it. The drug aims to lower a harmful protein that causes transthyretin amyloidosis, a serious disease affecting nerves and the heart. Participants rece…

This study tested a new drug called vutrisiran in 164 people with a rare inherited disease that damages nerves and organs. Participants received either vutrisiran as a shot every 3 months or the standard treatment patisiran as an IV infusion every 3 weeks. The goal was to see if …

This study tested a new medicine called ALN-AGT01 in 394 adults with mild-to-moderate high blood pressure. The goal was to see if it could safely lower blood pressure over three months. Participants received either the drug or a placebo, and blood pressure was measured continuous…

This study tested a new medicine called zilebesiran in 663 adults whose high blood pressure was not well controlled by their current pills. Participants received either zilebesiran or a placebo added to their usual treatment. The goal was to see if the new drug could lower blood …

This early-phase trial tested the safety and tolerability of a single dose of ALN-AGT01 RVR in 42 healthy adults. Participants received either the drug or a placebo by injection. The study is complete and focused on side effects and how the drug moves through the body.